<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976196</url>
  </required_header>
  <id_info>
    <org_study_id>08-104</org_study_id>
    <nct_id>NCT00976196</nct_id>
  </id_info>
  <brief_title>Platelet Hyperreactivity Project</brief_title>
  <acronym>PHP</acronym>
  <official_title>Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fontana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PHP study aims to delineate gene products involved in high on-treatment platelet
      reactivity in aspirin-treated cardiovascular patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PHP study aims to delineate gene products involved in high on-treatment platelet
      reactivity in aspirin-treated cardiovascular patients using a system biology approach that
      include proteomics analysis of selected platelet sub-fractions in patients displaying
      extreme phenotype.

      Main objective:

        -  to characterize the proteome profile of platelet hyperreactivity in aspirin-treated
           cardiovascular patients

      Secondary objectives:

        -  to characterize the platelet hyperreactivity phenotype in cardiovascular patients
           treated with aspirin

        -  to determine genetic polymorphisms associated with platelet hyperreactivity
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proteome profile of platelet hyperreactivity</measure>
    <time_frame>cross sectional</time_frame>
    <description>to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin</measure>
    <time_frame>cross sectional</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>genetic polymorphisms associated with platelet hyperreactivity</measure>
    <time_frame>cross sectional</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Platelet Reactivity</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma Serum Platelets
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic atherothrombotic patients treated with aspirin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented symptomatic ischemic atherothrombotic disease treated by aspirin.

        Exclusion Criteria:

          -  Known platelet disorder

          -  Chronic treatment by antiplatelet drugs other than aspirin

          -  Chronic anticoagulant treatment

          -  Chronic non steroidal anti-inflammatory drug treatment

          -  Active cancer

          -  Treatment with serotonin reuptake inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fontana, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>September 11, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Pierre Fontana</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Blood platelets</keyword>
  <keyword>proteomics</keyword>
  <keyword>Platelet reactivity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
